

UC Irvine

UC Irvine Previously Published Works

Title

Molecular mechanism for activation of the 26S proteasome by ZFAND5.

Permalink

<https://escholarship.org/uc/item/7w928915>

Journal

Molecular Cell, 83(16)

Authors

Lee, Donghoon

Zhu, Yanan

Colson, Louis

et al.

Publication Date

2023-08-17

DOI

10.1016/j.molcel.2023.07.023

Peer reviewed



Published in final edited form as:

Mol Cell. 2023 August 17; 83(16): 2959–2975.e7. doi:10.1016/j.molcel.2023.07.023.

Molecular mechanism for activation of the 26S proteasome by ZFAND5

Donghoon Lee^{1,*}, Yanan Zhu^{2,3,4,7,*}, Louis Colson^{2,*}, Xiaorong Wang⁵, Siyi Chen², Emre Tkacik², Lan Huang⁵, Qi Ouyang^{3,4,6}, Alfred L. Goldberg^{1,**}, Ying Lu^{2,8,**}

¹Department of Cell Biology, Harvard Medical School, Boston, USA

²Department of Systems Biology, Harvard Medical School, Boston, USA

³Center for Quantitative Biology, Peking University, Beijing, China.

⁴State Key Laboratory for Artificial Microstructures and Mesoscopic Physics, School of Physics, Peking University, Beijing, China

⁵School of Medicine, University of California Irvine, Irvine, USA

⁶Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

⁷Present address: Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK

⁸Lead contact

Summary

Various hormones, kinases, and stressors (fasting, heat shock) stimulate 26S proteasome activity. To understand how its capacity to degrade ubiquitylated proteins can increase, we studied mouse ZFAND5, which promotes protein degradation during muscle atrophy. Cryo-electron microscopy showed that ZFAND5 induces large conformational changes in the 19S regulatory particle. ZFAND5's AN1 Zn finger domain interacts with the Rpt5 ATPase and its C-terminus with Rpt1 ATPase and Rpn1, a ubiquitin-binding subunit. Upon proteasome binding, ZFAND5 widens the entrance of the substrate translocation channel, yet it associates only transiently with the proteasome. Dissociation of ZFAND5 then stimulates opening of the 20S proteasome gate. Using single-molecule microscopy, we showed that ZFAND5 binds ubiquitylated substrates, prolongs their association with proteasomes, and increases the likelihood that bound substrates undergo

**Correspondence: ying_lu@hms.harvard.edu (Y. L.) and alfred_goldberg@hms.harvard.edu (A. L. G).

*These authors contributed equally to this work

Author contributions

D. L., A. L. G and Y. L. conceived and designed the project. D. L. purified proteins and performed biochemical analysis. Y. Z. performed cryo-EM analysis and single-particle reconstruction of different proteasome states with ZFAND5. L. C. performed single-molecule fluorescence analysis. D. L. and S. C. performed live-cell analysis. L. H. and X. W. performed mass spec analysis. All authors participated in manuscript preparation.

Declaration of interests

The authors claims no competing interests.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

degradation, even though ZFAND5 dissociates before substrate deubiquitylation. These changes in proteasome conformation and reaction cycle can explain the accelerated degradation and suggest how other proteasome activators may stimulate proteolysis.

Blurb

Donghoon et al. report mechanistic insights into the reaction cycle of ZFAND5-mediated proteasome activation through transient interactions with the proteasome and substrate. ZFAND5 interaction and dissociation results in conformational changes of the proteasome which increase the likelihood of degradation of a proteasome-bound substrate. These results reveal how proteasomal degradation is activated through ZFAND5 expression under physiological conditions.

Graphical Abstract



Keywords

protein degradation; proteasomes; proteasome activation; ubiquitin; ZFAND5; muscle atrophy

Introduction

The 26S proteasome is the primary site of ubiquitin(Ub)-dependent protein degradation in eukaryotic cells. Protein ubiquitylation has been widely assumed to be the only regulated step in the ubiquitin-proteasome pathway. However, it is now well established that the

degradative capacity of the 26S proteasome is also tightly regulated and increases in a variety of conditions when overall protein degradation in the cell increases, including starvation, heat shock, or muscle atrophy¹⁻³. Under these conditions, Ub conjugates accumulate, and thus proteasome function limits the rate of proteolysis. For example, during muscle atrophy, as may result from denervation, disuse, fasting or cancer, muscles express the Zn-finger protein, ZFAND5/ZNF216, which binds to 26S proteasomes and enhances their ability to hydrolyze ubiquitylated proteins, ATP, and small peptides^{3,4}.

The molecular mechanisms that account for the more efficient degradation of ubiquitylated proteins under these various conditions are not well understood. The degradation of a ubiquitylated substrate is a multistep, ATP-dependent process that involves a series of conformational changes, especially in the 19S regulatory particle (RP)^{5,6}. The ubiquitylated substrate may first bind directly to the proteasome or bind indirectly via a “shuttling factor”⁷. However, it is now clear that most ubiquitylated proteins that bind to proteasomes surprisingly dissociate without becoming committed to translocation into the 20S core particle (CP) for proteolysis⁸. This poorly understood commitment step may involve the capture of an unstructured region of the substrate by the hexameric AAA+ ATPase ring, which drives substrate translocation⁹. These six ATPase subunits form a channel which during proteolysis become aligned with the gated pore in the CP’s outer α -ring⁷. Opening of this gate is triggered by the ATPases’ conformational changes and is essential for substrate entry and degradation.

Furthermore, to efficiently deliver a substrate into the CP, substrate-attached Ub chains need to be removed by the proteasome-associated deubiquitylating enzymes (DUBs), especially Rpn11. It remains unclear which of these essential steps are rate-limiting and how their structural transitions are regulated to promote degradation.

To understand the molecular basis of proteasome activation, we investigated ZFAND5, because of its importance in a variety of physiological processes which occurs primarily through increased proteolysis by the ubiquitin-proteasome system (UPS)^{10,1034}

By integrating cryo-EM structural determination with single-molecule kinetic analysis, we defined how ZFAND5 interacts with the 26S proteasome and activates it in substrate degradation. Our study shows that ZFAND5 reshapes the proteasome’s conformational landscape so as to increase the rate and efficiency of substrate degradation. The engagement of ZFAND5’s C-terminus with a regulatory site on Rpn1, induces a distinct 19S conformation that appears to favor substrate translocation and proteolysis. Surprisingly, ZFAND5’s rapid dissociation from the 26S also triggers key conformational changes that enable substrate translocation into the 20S CP.

Results

Defining the ZFAND5-proteasome interactions by cryo-EM and cross-linking mass spectrometry

To reveal the structural basis for the stimulation of proteasome activities by ZFAND5, we determined the cryo-EM structures of the human 26S proteasome in the complex

with recombinant mouse ZFAND5. The presence of ZFAND5 significantly altered the conformational landscape of the proteasome. Unsupervised 3D classification identified eight distinct states—designated Z_{+A} to Z_{+E} and Z_{-A} to Z_{-C} with nominal resolutions of 3.6Å - 4.8Å (Fig. 1A; Fig. S1–S3). Five of them were designated Z_{+} states because they contain an extra density that can be fitted with an NMR structure of ZFAND5's AN1 domain (amino acids 148–194) (PDB: 1WFL) which was extended using a structural prediction with AlphaFold¹¹. Z_{+A} comprised 20.5% of the particles, Z_{+B} 22.4%, Z_{+C} 7.3%, Z_{+D} 11.5%, and Z_{+E} 7.2%. The other three states were named Z_{-} , because they lack any ZFAND5 density; Z_{-A} comprised 8.5% of the particles, Z_{-B} 8.5% and Z_{-C} 14.8%.

In the Z_{+} states, ZFAND5's AN1 domain (residues R169 and D182) docks at the RP-CP boundary and interacts with both the large and the small domains of the ATPase subunit, Rpt5 (at residues Q184 and R364), and with the CP subunit, $\alpha 7$ (at residue V204) (Fig. 1B–D). To examine whether ZFAND5 may interact with additional sites that were not detected by cryo-EM, we cross-linked the ZFAND5–26S complex with disuccinimidyl sulfoxide (DSSO) which is reactive to primary amines and identified the cross-linked peptides, that were generated by trypsinization using mass spectrometry in a similar approach as used previously to define the detailed interactions between different proteasome subunits¹². Consistent with the cryo-EM result, lysine residues mainly in the C-terminus of ZFAND5 were cross-linked to lysines in the ATPase domain of Rpt5 (Fig. 1E and Table S1). No other 19S subunit was cross-linked to ZFAND5.

The $Z_{+A, B, C}$ states, which together comprised 54% of the particles, closely resemble the proteasome in the resting, or S_A , state seen in the absence of ZFAND5 (RMSD=1.95Å)¹³, with minor differences in the configurations of the non-ATPase subunits, Rpn1 and Rpn2 (Fig. S3E–S3I). The C-termini of Rpt3 and Rpt5 were found inserted into the inter-subunit pockets in the CP's α -ring in these three states (Fig. S4A). These arrangements closely resemble those in the S_A state¹³. As in that state the substrate translocation channel in the RP ATPases is not aligned with the gated entry channel in the CP. The Z_{+E} state also resembles S_A or Z_{+A} , except that its Rpn5 subunit only shows a partial density indicating structural flexibility (Fig. S4B). In these states, we did not resolve the regions that are N or C-terminal to ZFAND5's AN1 domain, also likely due to structural flexibility of these regions.

ZFAND5 C-terminal region interacts with Rpn1-Rpt1 in a distinct RP conformation with an open substrate-translocation channel

The Z_{+D} state represents a RP conformation that is distinct from either the resting or translocating states of the proteasome^{6,13,14}. Most subunits in the Lid subcomplex in Z_{+D} exhibit a $\sim 5^\circ$ clockwise rotation around the central axis, which causes these subunits to deviate by 5Å \sim 10Å from their resting locations in the Z_{+A} or S_A state (Fig. 2A). The arrangement of the ATPases, the pore loops and the status of nucleotide pockets in Z_{+D} also differed from those in other states (Fig. S5 and S6).

The most striking feature of the RP in Z_{+D} is its wide-open entrance to the substrate translocation channel, a rigid ring formed by the OB domains of the ATPases, which is

partially occluded in the resting states, such as Z_{+A} and S_A ^{13,15}. The diameter of the unobstructed portion of the entrance to the channel in Z_{+D} is 25Å compared to 8Å in the other Z_{+} states presumably as a result of the Lid rotation (Fig. 2B). Opening of the translocation channel probably also results from the displacement of a helix domain of Rpn3 (Fig. 2C). This helix is sandwiched and is stabilized by Rpn11 and the OB domain of Rpt3, and rests above the OB ring, so as to occlude the translocation entrance in the S_A state (Fig. 2C).

In the Z_{+D} map, a density that corresponds to the C-terminal region (CTR, amino acids 195–213) of ZFAND5 is clearly visible, which is not evident in the Z_{+A} , B , C states. This density extends from ZFAND5's AN1 domain, loops over and arrives at a cavity that is adjacent to Pro719 in the convex side of the toroidal domain of the non-ATPase subunit Rpn1 and is also flanked by the OB domain of the ATPase Rpt1 (Fig. 1C). This binding site on Rpn1, which we term the Z site, was previously not known to be involved in protein-protein interactions and is separate from the T1 and T2 sites on Rpn1, which are located on the opposite side of Rpn1 and bind Ub and UBL-domain-containing proteins (Fig. 1D)¹⁶. The functional importance of these interactions is studied below.

In Z_{+D} , ZFAND5's CTR forms additional contacts with the RP and is likely stabilized by these interactions. A short helix emerges adjacent to ZFAND5's AN1 (residues N202 and P203) and interacts with another ATPase Rpt1 through helix 5 in Rpt1's AAA domain (at residues V202 and N314) (Fig. 1C and 1D). Beyond Rpt1, ZFAND5's residues are also engaged in specific interactions with a C-terminal fold of Rpn1, which may help position ZFAND5's C-terminus (the residues K209 and I213) to the Z site in the toroidal cavity of Rpn1 (at residues P719 and V850) (Fig. 1D and 1E). To accommodate ZFAND5, a Rpn1 helix (Asp346-Gly360) that interacts with Rpt1 in the S_A state is displaced and joins the toroid of Rpn1 in Z_{+D} . This change may destabilize Rpn1-Rpt1 interaction and causes a ~30° rotation of Rpn1 away from Rpt1 in Z_{+D} (Fig. S7A). Interestingly, the local resolution of Rpn1 in Z_{+D} is significantly higher than that in the other states, indicating that docking of ZFAND5's CTR probably stabilizes the configuration of Rpn1 in the RP (Fig. S7B). These residues involved in ZFAND5's CTR-19S interactions are highly conserved in high eukaryotes (Fig. S8).

Upon dissociation ZFAND5 promotes translocation-competent proteasomal states

Translocation of the protein substrate into the CP requires both the opening of the gated pore in its α -ring and the alignment of the 19S ATPase channel with this open gate. Gate opening in the CP is controlled by conformational changes of the ATPases^{5,6,17,18}. Surprisingly, the CP gate is in a closed conformation in all the Z_{+} states that contain a ZFAND5 density, but it adopts an open conformation in all the Z_{-} states (Fig. S4A). In addition, in all these Z_{-} states, the substrate translocation channels in the RP and the CP are aligned, which is a characteristic feature of proteasomes active in degradation^{5,6,15}. The Z_{-A} and Z_{-C} states resemble respectively the translocation-competent ED1 and ED2 structures of the substrate-engaged human proteasome (or 5D and 4D for yeast 26S), with respect to both the RP geometry and the nucleotide-binding status, although no ubiquitylated substrate was included in the cryo-EM sample (Fig. S6, S7C and Table S2)⁶. ZFAND5 was not degraded

by the 26S, and its level was stable during the incubation with the proteasome (Fig. S9A and S9B).

The exposure to ZFAND5 dramatically enlarged the population of open-gated particles, which increased from 7.9% in the 26S sample without ZFAND5¹³ to 31.8% in its presence (Table S2). Substrate translocation into the CP requires an open gate (i.e. a **Z⁻**) conformation. Because ZFAND5 was not present in these particles, the transition of the proteasomes into a translocation-competent, **Z⁻** state must occur upon ZFAND5 dissociation. Direct evidence for this conclusion is shown below.

Further evidence for the increase in gate-opening was obtained using an activity-based probe (yellow Bodipy-Cy3-epoxomicin, MVB003). This agent covalently modifies the active sites within the 20S core particle¹⁹, and thus rapid derivatization of these subunits is a measure of their accessibility. Exposure of proteasomes to ZFAND5 dramatically increased their covalent modification (Fig. 2D and S9C), as expected from the large increase in open-gated particles.

This increase in the open-gated population can account for the large stimulation of peptide hydrolysis by ZFAND5 seen previously³. This stimulation requires the AN1, but not the A20 domain of ZFAND5. To test the dependence on ZFAND5's CTR, we truncated ZFAND5's C-terminus by 19 amino acids (ZFAND5^{-C}). ZFAND5^{-C} maintained the interaction with the proteasome in a co-precipitation assay (Fig. 2E), but it could not stimulate peptide hydrolysis (Fig. 2F). In addition, both the doubly- and singly-capped proteasomes migrated more slowly in native-gel electrophoresis after exposure to ZFAND5, which probably reflects the large conformational changes in the RP³. However, neither ZFAND5^{-C} nor ZFAND5 with a mutated AN1 domain slowed proteasome migration in native PAGE (Fig. 2G and S9D). Therefore, the activation of the 26S proteasome through transition into the open-gated **Z⁻** states requires ZFAND5's CTR. In addition, because the CTR does not appear to interact with proteasome in the **Z^{+A,B,C,E}** states, transition into **Z⁻** presumably follows the formation of the **Z^{+D}** state.

We then tested whether ZFAND5 expression caused a similar increase in the open-gated population of intracellular proteasomes, as was shown with purified particles (Fig. 2D). C2C12 myotubes were incubated for one day with dexamethasone, which induces ZFAND5, and then were exposed for 1h with the membrane-permeant fluorescent probe MVB003. Although the myotube content of 19S (Rpt5) or 20S (β 5) particles did not change with dexamethasone, the reactivity of 20S active sites increased dramatically (Fig. 2H). Thus, in cells, ZFAND5 seems to increase the fraction of particles in an open-gated conformation, as observed with purified particles.

ZFAND5 accelerates proteasomal degradation of ubiquitylated substrates

In order to understand the functional effects of ZFAND5-induced structural changes, we next studied the degradation of ubiquitylated proteins in the presence of ZFAND5. We used a fluorescent model substrate containing the N-terminal region of cyclinB (cycB) fused to a destabilized fluorescent protein cpGFP^{20,21}, and studied how proteasome activation

depends on ZFAND5's structural domains. Ubiquitylation of cycB-cpGFP by the E3 Anaphase-Promoting Complex (APC/C) leads to efficient and processive degradation by purified 26S proteasomes (Fig. 3A), with little deubiquitylation or partial cleavage of the substrate (Fig. S10A). This reaction appeared to obey the Michaelis-Menten kinetics, and a Lineweaver–Burk analysis indicated an apparent K_M of 5.6nM for this substrate (Fig. S10B). The turnover time for this substrate was 46 seconds/substrate/proteasome at substrate concentrations above the K_M . Most of our subsequent experiments were performed under multiple-turnover conditions with a large substrate excess.

Degradation of ubiquitylated cycB-cpGFP proceeded in different phases. The apparent degradation rate was slower in the late phase (“II”, 5.9 minute/substrate) than in the initial phase (“I”, 0.59 minute/substrate) (Fig. 3A). ZFAND5 increases the initial degradation rate by 24%, but the late phase of the reaction by 71% (Fig. 3A) with $K_a \sim 100$ nM (Fig. S10C). Preincubation of ZFAND5 with either the substrate or the proteasome further increased its stimulatory effect (Fig. S10D). This lower degradation rate in phase II is unlikely to be due to substrate depletion, because the remaining substrate concentration measured by GFP intensity was still much higher than the K_M of 5.6nM (Fig. S10B), nor was it caused by a loss of proteasome activity during incubation, since we recorded an almost identical degradation rate by adding a second dose of ubiquitylated cycB-cpGFP during phase II of the reaction (Fig. S10E). Also, ZFAND5 is not consumed during these incubations with the proteasome and the ubiquitylated substrate (Fig. S10F).

One contributor to this multi-stage kinetics is substrate heterogeneity. The Ub conjugates formed on cyclin-B by APC/C vary in their configurations of Ub moieties²² which determine their susceptibility to proteasomal degradation⁸. Since the Ub copy number is a key determinant of the degradation rate⁸, we measured the rates of degradation of cycB-cpGFP conjugated with different numbers of Ub moieties. While ZFAND5 increased the hydrolysis of all ubiquitylated cyclinB species, substrates containing 4–6 Ub moieties were stimulated to the greatest extent (Fig. 3B). Thus, ZFAND5 appears to have a larger effect on substrates with intermediate Ub copies that are suboptimal for proteasome recognition.

Inactivating either the Zn finger domains of ZFAND5, the AN1 domain or the Ub-binding A20 domain, largely abolished the stimulation of the degradation of cycB-cpGFP (Fig. 3C)³. Also, as found for peptide hydrolysis (Fig. 2F), ZFAND5's CTR is required for the enhanced cycB degradation (Fig. 3C). While the A20 domain must function in Ub conjugate binding, the requirement for the C-terminus and AN1 domain implies that their interactions with the Rpn1, Rpt1 and Rpt5 in the $Z+A$ to $Z+D$ conformations are also critical for the accelerated proteolysis.

ZFAND5 accelerates the degradation of model UPS substrates in cells

In MEF cells lacking ZFAND5 the overall rate of degradation of cellular proteins is reduced, and its induction appears essential for the rapid acceleration of overall proteolysis during muscle atrophy^{3,4}. However, ZFAND5's effects on the degradation of specific proteins in cells have not been investigated. Therefore, we examined the effects of ZFAND5 expression on the half-lives of two well-studied model substrates of the UPS, Ub-R-YFP, a substrate of the N-end rule pathway, and of Ub(G76V)-YFP, which is ubiquitylated by the Ub-fusion-

degradation (UFD) pathway. These constructs were co-expressed with WT or ZFAND5 mutants in HEK293T cells, and we used time-lapse microscopy to quantitatively study their degradation in individual cells after addition of cycloheximide to block protein synthesis.

In cells expressing these reporters at high levels (5~15uM), ZFAND5 markedly shortened the average half-life of both (Fig. 3D). Importantly, their degradation was not accelerated upon expression of ZFAND5 mutants lacking the A20 or AN1 domains or its C-terminus, as was found for the degradation of cycB fusions proteins by purified proteasomes (Fig. 3D). Because ZFAND5 is not known to interact with other factors that are required for the degradation of these reporters, the most likely explanation for this result is that ZFAND5 in cells stimulates the degradation of these reporters by activating the proteasome, through the same mechanisms studied *in vitro*. However, co-expressing ZFAND5 did not significantly alter the stability of these proteins in low expressing cells, presumably because the rate of reporter degradation is not limited by the proteasome activity.

To learn if ZFAND5 can also stimulate the degradation of the diverse Ub conjugates found *in vivo*, we isolated Ub conjugates from growing HEK293 cells stably expressing polyHistidine-HA tagged Ub and added N-ethylmaleimide to inhibit hydrolysis of Ub conjugates by DUBs. When these proteins ubiquitylated in the cell were incubated with purified proteasomes in the presence of ZFAND5 for 30min, we observed a stimulation of Ub conjugate degradation, as indicated by the greater decrease in K48 Ub chains (Fig. 3E). This capacity to increase degradation of ubiquitylated proteins presumably accounts for the enhancement by ZFAND5 of degradation of endogenous proteins in cells and in crude extracts³.

ZFAND5 promotes the degradation of difficult-to-unfold substrates

The rate of substrate degradation by the proteasome is limited not only by the nature of the Ub modification but also by structurally stable domains that exist in many cellular proteins. Substrates with these types of domains, after proteasome binding, may resist unfolding, deubiquitylation or proteolysis and may cause incomplete (non-processive) degradation with the release of partially digested fragments²³. To study the effect of ZFAND5 on the degradation of such hard-to-unfold substrates, we fused cycB with the fluorescent protein EGFP, which the 26S proteasome by itself degrades much more slowly than cpGFP (as measured by the loss of the fluorescence signal), even when their levels of ubiquitylation were similar (Fig. S11A)²¹.

However, in the presence of ZFAND5 the degradation rate of the EGFP moiety was stimulated by 70% which was greater than the fold change seen with cycB-cpGFP (although the absolute degradation rate of the hard-to-unfold substrate was still slower than that of cpGFP) (Fig. 4A and S11B).

A western blot analysis of the products released by the proteasome indicated that ZFAND5 greatly accelerates both the deubiquitylation and non-processive degradation of cycB-EGFP as well as its complete hydrolysis, which was dependent on ubiquitylation of the substrate (Fig. 4A and S11C). The stimulation of all these proteasomal activities also requires ZFAND5's AN1, A20, and C-terminal domains (Fig. 4B). In the presence of ZFAND5,

removal of the Ub chains from this substrate was complete within about 30 minutes, which is much faster than the deubiquitylation rate without ZFAND5. As expected^{24,25}, deubiquitylation of cycB-EGFP was blocked by the Zinc chelator, 8-mercaptoquinoline (8MQ), but was not affected by Ubiquitin Vinyl Sulfone (Ub-VS), an inhibitor of cysteine DUBs (Fig. 4C). Thus, this process is driven mainly by the metalloprotease Rpn11, which resides at the entrance to the ATPase channel. Inhibition of Rpn11 did not prevent ZFAND5's stimulation of the degradation of the peptide substrate (Fig. S11D).

Processing of difficult-to-unfold substrates can lead to proteasome inhibition through the formation of stable (non-degraded) intermediates^{24,26}. In these experiments, both deubiquitylation and partial degradation significantly slowed down after 10 minutes in the absence of ZFAND5, probably because of proteasome inactivation by some substrate molecules (Fig. 4A). In contrast, degradation of the hard-to-unfold substrate did not terminate rapidly when ZFAND5 was present, which suggests that the ZFAND5-activated proteasomes resisted such inhibition.

A peptide corresponding to ZFAND5's C-terminal residues by itself can stimulate proteasome activities

Both our structural and mutation studies suggest the functional importance of ZFAND5's C-terminal residues. To further explore the activity of ZFAND5's CTR, we synthesized a peptide corresponding to residues 195–213 and tested whether by itself this 19-residue peptide might influence proteasome activities. Surprisingly, the addition of this peptide alone stimulated peptide hydrolysis 2.5-fold (Fig. 5A) and also enhanced the hydrolysis of ubiquitylated cycB, primarily in the initial phase of the degradation reaction (Fig. 5B). These stimulatory effects were smaller than those of full-length ZFAND5, which increased peptide hydrolysis by up to 10-fold and stimulated cycB degradation in both phase I and II (Fig. 3A). By contrast, if a 19-residue peptide from an unrelated protein was added, proteasome activity did not increase. Interestingly, we found that N-terminal acetylation of the CTR peptide also attenuated the stimulation. By contrast, neither the isolated A20 nor the isolated AN1 domain of ZFAND5 could enhance the proteasome's peptidase activity³. Then, we examined if CTR peptide binds to the same site and competes with 26S-bound ZFAND5. When the CTR peptide was present at the same concentration as that enhances the 26S peptidase activity, the proteasome-bound full-length ZFAND5 clearly reduced, suggesting that the CTR peptide and ZFAND5 compete for binding to the 26S (Fig. S12). These findings make it very likely that the **Z+D** state, in which ZFAND5's CTR interacts with Rpn1 and Rpt1, is a key intermediate in proteasome activation, and that these interactions are both necessary and sufficient to induce many of the conformational changes leading to gate opening and enhanced proteolytic activity.

The interactions of ZFAND5's C-terminal residues with the RP are important for proteasome activation

To further investigate the role of ZFAND5' CTR interactions with Rpn1 and Rpt1 in proteasome activities, we examined the effects of the specific residues' interactions by site-directed mutation. A total of seven mutations, single, double or four residues to alanine, where four residues apparently interact with Rpn1 (i.e. K209 and I213) or Rpt1 (i.e. N202

and P203) were made. Intriguingly, mutation of individual residues caused a decrease in the 26S peptidase activity and hydrolysis of the ubiquitylated substrate (Fig. 5C and 5D). Double mutations at the residues interacting with Rpn1 or Rpt1 further lowered the stimulatory effect of ZFAND5, and mutations at all four residues blunted the stimulation of both peptidase and the degradation of Ub conjugates. It is noteworthy that the effect of loss of the Rpn1 interactions (i.e. both K209A and I213A) appears as strong as the mutations at all four residues. This result confirms that the conformational changes induced by the CTR-RP interactions are critical for the stimulation of 26S activity.

Single-molecule analysis of ZFAND5-substrate-proteasome interactions

To further understand the mechanism of proteasome activation by ZFAND5, we investigated the kinetics of the key steps in the degradation process using single-molecule fluorescence microscopy. We first examined the ZFAND5-proteasome interactions. Purified 26S proteasomes were immobilized on a passivated glass surface via an anti-20S antibody (Fig. 6A). The binding of ZFAND5, which had been fluorescently labeled using an N-terminal SNAP tag, was monitored by Total Internal Reflection Fluorescence (TIRF) microscopy. The presence of the SNAP-tag did not affect the ability of ZFAND5 to stimulate the proteasome's peptidase activity (Fig. S13A).

ZFAND5 associated transiently with the proteasome. The distribution of ZFAND5's dwell time ($\sim 1/k_{\text{off}}$) on the proteasomes indicated at least two exponential modes, with time constants of 50 ± 15 ms and 614 ± 350 ms respectively (Fig. 6B; Fig. S13B). Based on our Cryo-EM analysis, we hypothesized that engagement of ZFAND5's CTR with Rpt1 and Rpn1 may stabilize the ZFAND5-proteasome interaction and account for the long-binding mode.

Accordingly, deletion of the 19 C-terminal residues of ZFAND5 reduced the long-binding component by about 10X (Fig. 6C; Fig. S13C). Thus, the ZFAND5-proteasome interaction is stabilized by the CTR, most likely through its engagement with Rpn1 and Rpt1. Interestingly, the addition of ATP- γ S promoted the long-binding mode, suggesting that efficient dissociation of ZFAND5 from the proteasome requires ATP hydrolysis, a process that is also stimulated by ZFAND5³.

We next examined ZFAND5's affinity for ubiquitylated substrates. ZFAND5 was directly immobilized onto the surface via the SNAP tag and was incubated with polyubiquitylated securin (Fig. 6D), in which the Ub molecules were fluorescently labeled, so that the number of Ubs on the substrate molecule could be determined by the fluorescence intensity of the substrate spot⁸. The substrate's dwell time on the surface increased with the increase of the Ub stoichiometry, suggesting an avidity effect in the interaction of ZFAND5 with the ubiquitylated protein (Fig. 6E).

The A20 domain on ZFAND5 and other proteins is essential for binding Ub chains²⁷. Surprisingly, ZFAND5's C-terminal residues also appear to be directly involved in the substrate interaction, since the dwell time of ubiquitylated securin on the surface-immobilized SNAP-tagged ZFAND5 C was much shorter than that of WT ZFAND5 (Fig.

6E). Because this CTR lacks a recognizable Ub-interacting motif, the molecular basis for this effect on substrate binding is still unclear.

The addition of ZFAND5 increased the total amount of substrate-bound proteasome particles. This effect was at least in part due to prolongation of the substrate's dwell time on the proteasome (Fig. 6F and 6G). Ub conjugates showed a similar dwell time on the surface-immobilized proteasomes as on ZFAND5. ZFAND5 appeared to increase most the dwell time of substrates bearing 3–5 Ubs, which correlates with the optimal Ub stoichiometry for the stimulation of proteolysis by ZFAND5 (Fig. 3B). As expected, the Ub-interacting A20 domain of ZFAND5 is essential for the dwell time enhancement, as a mutation inactivating the A20 Zn finger largely abolished this effect, without affecting the ZFAND5-proteasome interaction (Fig. 6G). Interestingly, mutating the AN1 domain resulted in an even shorter dwell time than that seen with the Ub conjugates in the absence of ZFAND5. Presumably this decrease in dwell time contributes to the inability of these mutants to stimulate Ub conjugate degradation (Fig. 3C). The CTR of ZFAND5, which is essential for stimulating Ub conjugate degradation, is also required for the dwell-time enhancement. Since the proteasome interacts with ZFAND5 more transiently than with the substrate, ZFAND5 prolongs the substrate's dwell time most likely through altering the proteasome's conformations, rather than by of continuing to function in a substrate-ZFAND5–26S complex (e.g. as an alternative 19S substrate receptor).

ZFAND5 increases the likelihood of a proteasome-bound substrate undergoing degradation

Most of the ubiquitylated substrates that bind to the 26S proteasome dissociate without degradation⁸. We therefore examined if ZFAND5 would affect the likelihood that a proteasome-bound substrate will undergo processive deubiquitylation and proteolysis. To this end, we used the rapid and 'stepped' decrease of Ub intensity in single-molecule traces as a signature for substrate deubiquitylation and translocation (Fig. 7A)⁸. The cycB substrate contains multiple Ub chains formed by the APC/C. These chains are deconjugated co-translocationally by Rpn11, resulting in 'stepped' Ub signal reductions which typically are completed within 10~20 seconds. In the absence of ZFAND5, only a small fraction (~14%) of substrate-proteasome encounters resulted in deubiquitylation and translocation, as was observed previously (Fig. 7B)⁸. In contrast, ZFAND5 increased the fraction of such events from 14% to 23%, and this increase in the likelihood of degradation required the presence of ZFAND5's CTR and its A20 and AN1 domains (Fig. 7B).

The increased probability of a bound substrate being degraded is not a simple consequence of its longer dwell time on the proteasome. At least for substrates with more than four Ubs, their dwell time on the proteasome is significantly longer than the average latency period of ~2 seconds before the first deubiquitylation event, and therefore dwell time is not limiting for their degradation⁸. Furthermore, the addition of ZFAND5 or its mutants does not significantly alter the interval from the initial substrate-proteasome encounter to the first or second deubiquitylation events (Fig. S14A), suggesting a dwell-time-independent mechanism enhances the degradation of these substrates that already have a high affinity for the proteasome.

ZFAND5 does not boost the speed of translocation. We aligned the traces showing processive deubiquitylation by the moment of substrate binding and then calculated the average Ub intensity among these traces at each time point. We used the decay rate of the averaged trace as a measure of the speed of translocation^{8,26}. Neither ZFAND5 nor its mutants significantly affected the translocation speed of these substrates (Fig. S14B). This lack of effect on substrate translocation is consistent with our finding by cryo-EM that ZFAND5 is absent from the open-gated (i.e. translocation competent) **Z₋** states.

The long-binding mode of ZFAND5 favors substrate degradation

To examine whether **Z_{+D}** state that features a wide-open entrance to the ATPase channel may underlie the increased substrate degradation by ZFAND5, we simultaneously recorded Ub's and ZFAND5's fluorescence signals in a dual-color single-molecule measurement (Fig. 7C). A variety of events were detected, which we first classified according to whether they were linked to processive deubiquitylation. ZFAND5 interacted with the proteasome transiently even in the presence of substrate. The median dwell time of ZFAND5 on the proteasome was 1.3s, if ZFAND5 binding occurred within 2s of the substrate binding and was associated with processive deubiquitylation (Fig. 7C and 7D). However, its dwell time was much shorter when ZFAND5's binding events were not associated with substrate deubiquitylation. Because the **Z_{+D}** state with its characteristic CTR-Rpn1-Rpt1 interactions appears responsible for the long-binding mode of ZFAND5, which is associated with substrate deubiquitylation, the **Z_{+D}** state is very likely to be a critical step in ZFAND5's stimulation of proteasomal degradation.

Simultaneous ZFAND5 and substrate binding to the proteasome maximally stimulates proteolysis

We then compared the fractions of deubiquitylation events that occurred when ZFAND5 bound shortly before, together with, or shortly after the ubiquitylated substrate (Fig. 7E). Simultaneous binding (within one frame) of ZFAND5 and the substrate to the proteasome led to processive deubiquitylation and translocation in 65% of the cases, which is much higher than the likelihood of translocation (19%) seen without ZFAND5. When ZFAND5 binding preceded or followed substrate binding, it also increased the likelihood of degradation, but to a smaller extent.

The accelerated degradation of ubiquitylated substrates by ZFAND requires its A20 domain which interacts with Ub (Fig. 3C). To clarify further the function of A20, we analyzed their effects on the relative timing of the substrate binding to the 26S. Mutating the A20 domain or truncating the CTR decreased the probability of simultaneous binding of ZFAND5 and substrate to the proteasome, which is consistent with the importance of these domains in mediating substrate-ZFAND5 interaction (Fig. 7F). Thus, the timing of ZFAND5 and substrate binding to proteasome, which is mediated by the A20 and the CTR, determines the magnitude of the stimulation of conjugate degradation.

ZFAND5 dissociates from the proteasome before substrate deubiquitylation and degradation

When the events where ZFAND5 and substrate bound simultaneously were aligned by the moment of initial substrate binding, the averaged signal from the ZFAND5 channel revealed that it participated only in the early stages of the degradation process. After substrate translocation started, ZFAND5 rapidly dissociated from the proteasome (Fig. 7G), as was also suggested by our structural analysis (Fig. 1). Similar rapid dissociation of ZFAND5 was evident when we analyzed only the deubiquitylation events (Fig. S14C). The loss of ZFAND5's CTR significantly reduced its dwell time and substrate processing after the simultaneous binding, which further supports our conclusion that ZFAND5's long-binding mode on the proteasome requires the CTR-dependent $Z+D$ state and is critical in the acceleration of proteolysis. Together, these results indicate that ZFAND5 increases the likelihood that a bound substrate is committed to proteolysis through a series of coordinated events (Fig. 7H). To achieve this most effectively, ZFAND5 binds to the proteasome together with the ubiquitylated substrate. ZFAND5 then quickly dissociates, which transitions the proteasome to translocation-competent $Z-$ states, where the gate in the CP is open and aligned with the ATPases (Fig. 7H).

Discussion

Molecular Mechanisms of Proteasome Activation

In this study, we explored the molecular mechanisms for the acceleration of Ub conjugate degradation induced by an important regulator, ZFAND5. Through a combination of Cryo-EM and single-molecule kinetic analysis, we have elucidated a coherent sequence of events underlying the ZFAND5-induced enhancement of 26S proteasome function, which hopefully will illuminate the mechanisms for proteasome activation by other physiological factors.

As summarized in Fig. 7H, (1) ZFAND5 stimulates most effectively when it initially associates with a ubiquitylated substrate through its A20 domain and its CTR and then together with the substrate binds to the proteasome. (2) On the proteasome, ZFAND5's AN1 domain docks onto the Rpt5 ATPase subunit, which may release its CTR from the substrate, enabling it to engage with Rpt1 and Rpn1 on its Z site. (3) The binding of the ZFAND5's CTR to Rpt1 and Rpn1 induces a distinct conformation ($Z+D$) with a greatly enlarged ATPase channel, which should strongly facilitate substrate capture by the ATPases and the subsequent translocation. These interactions of the CTR with Rpt1 and the Z region of Rpn1 are of special regulatory importance, since a 19-residue CTR peptide can by itself enhance proteasomal hydrolysis of peptides and ubiquitylated proteins (see below). (4) ZFAND5 interacts only transiently with the proteasome and the substrate, and then rapidly dissociates, perhaps through an ATPase-driven step. (5) Importantly, its dissociation from the RP then converts the proteasome into a translocation-competent ($Z-$) state in which the CP gate that controls substrate entry is open and is aligned with the translocation channel in the RP. (6) Although the rate of substrate translocation does not appear to be accelerated, the likelihood that a bound Ub conjugate becomes committed to degradation is markedly increased through this sequence of events.

It was initially puzzling to find that ZFAND5 could stimulate proteasomal degradation even though it was only present in the translocation-incompetent (i.e. closed-gate) states. However, our dual-color single-molecule experiment (Fig. 7) showed that ZFAND5 functions primarily at the initial steps in this sequence, and that its dissociation precedes deubiquitylation and transition to translocation-competent Z^- states, some of which had only been observed previously in substrate-engaged 26S structures⁸. The transition into these Z^- states requires and likely follows the open-entry $Z+D$ state, because the ZFAND5's CTR is essential for stimulating the 26S's proteolytic activities, but not for the initial interaction with the proteasome (Fig. 3, 5 and 7). Although ZFAND5 stimulates proteolysis most effectively, when it binds to the proteasome together with the ubiquitylated substrate, there exists a short time window of approximately ± 2 sec after the binding of either the substrate or of ZFAND5 during which a stimulatory effect of ZFAND5 is manifest. Presumably this means that the ubiquitylated substrate can utilize these ZFAND5-induced transitions even if not initially bound to ZFAND5. This conclusion is also supported by our observations with the 19 residue CTR peptide, which lacks the Ub conjugate-binding A20 domain, but still stimulates proteasomal activities.

While ZFAND5 and other activators of the 26S proteasome (e.g. PKA or PKG) appear to enhance overall proteolysis in cells^{3,28}, they probably do not stimulate the degradation of all ubiquitylated cell proteins similarly. In our experiments using substrates of the N-end rule pathway and the UFD pathway, ZFAND5 expression increased their degradation, which depends on its A20, AN1 and CTR domains, similarly as in the purified reactions. Also, the degree of activation by ZFAND5 depends on the number of Ub on the substrate and perhaps on the pattern of ubiquitylation. Exactly how the A20 domain and the CTR of ZFAND5 interact with Ub conjugates is still unclear.

ZFAND5 affects multiple steps in the degradative process, and it is unlikely that any specific step in this reaction cycle by itself accounts for the more rapid degradation. ZFAND5's capacity to enhance substrate association with the proteasome (i.e. prolong dwell time), to enlarge the entrance into the ATPase channel, and upon dissociation to induce CP gate-opening all seem likely to help stimulate proteolysis. Our experiments with difficult-to-degrade substrates suggested that ZFAND5 may also increase their deubiquitylation by Rpn11, which can be a rate-limiting step for proteolysis. It is also noteworthy that even in the absence of a substrate, ZFAND5 stimulates ATP hydrolysis by the proteasome³.

Biological implications and potential applications of these findings

In muscle during fasting or atrophy, when overall rates of proteolysis rise, the levels of ubiquitylated substrates also are increased²⁹; thus proteasomal function must limit the rate of degradation, and 26S activation would seem important for the rapid loss of muscle mass. The important role of ZFAND5 in the accelerated proteolysis driving muscle atrophy implies that inhibitors of its actions may have therapeutic applications in combatting the debilitating loss of muscle mass seen with nerve injury, inactivity and many systemic diseases (e.g. cancer cachexia, cardiac and renal failure, excess glucocorticoids). Our identification of the critical interactions between ZFAND5 and the proteasome, especially those between its CTR

and Rpt1 and Rpn1's Z-site should facilitate the development of small molecule inhibitors of ZFAND5-dependent muscle wasting.

Limitations of the study

Here, we presented structural, functional and kinetic measurements to elucidate the mechanism of proteasome activation by its cofactor ZFAND5 which has been implicated in several important biological processes. However, it is still unclear whether ZFAND5 affects all proteasome substrates equally or imposes a selectivity which may be important for understanding its biological functions. Technically, combining substrates with ZFAND5 in structural study may provide further insights into the activation process, and more accurate single molecule imaging analysis requires fluorescent substrates with defined ubiquitin configuration. Moreover, the cell contains a number of factors and modifications that are able to activate the proteasome. Further studies should address these questions and uncover the complex regulation of proteasome activity and its role in protein homeostasis.

STAR★METHODS

RESOURCE AVAILABILITY

Lead contact—Ying Lu, Ph. D. Dept. of Systems Biology, Harvard Medical School
ying_lu@hms.harvard.edu

Materials availability—The following materials are available through contact

1. Plasmids of ZFAND5 or mutants, for expression in either bacteria or mammalian cells
2. Purified ZFAND5 protein
3. Purified ZFAND5 C-terminal peptide.

Data and code availability—Cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB) under accession codes EMD-14201 (Z_{+A}), EMD-14202 (Z_{+B}), EMD-14203 (Z_{+C}), EMD-14204 (Z_{+D}), EMD-14205 (Z_{+E}), EMD-14209 (Z_{-A}), EMD-14210 (Z_{-B}), EMD-14211 (Z_{-C}). Coordinates are available from the RCSB Protein Data Bank under accession codes 7QXN (Z_{+A}), 7QXP (Z_{+B}), 7QXU (Z_{+C}), 7QXW (Z_{+D}), 7QXX (Z_{+E}), 7QY7 (Z_{-A}), 7QYA (Z_{-B}), 7QYB (Z_{-C}). Data generated in this study have been deposited on Mendeley Data and are publicly available as of the date of publication. DOI for the deposited data is DOI: [10.17632/wkw5y7xzb3.1](https://doi.org/10.17632/wkw5y7xzb3.1)

- This paper does not report original code
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Cell Culture—HEK293 cells were cultured in DMEM medium containing 10% fetal calf serum (Gibco), supplemented with 1x antibiotic-antimycotic reagent (Gibco).

METHOD DETAILS

Proteasome expression and purification—Human proteasomes were purified through affinity chromatography on a large scale from a stable HEK293 cell line with RPN11-HTBH (hexahistidine, TEV cleavage site, biotin, and hexahistidine)³⁰. The harvested cells were homogenized with a Dounce homogenizer (type B pestle or equivalent tight one) in a lysis buffer (50 mM NaH₂PO₄, pH 7.5, 100 mM NaCl, 5 mM MgCl₂, 0.5% NP-40, 5 mM ATP, 1 mM DTT) containing protease inhibitor cocktail (Roche, Germany). The lysates were cleared, and incubated with the NeutrAvidin agarose beads (Thermo Fisher Scientific, MA, USA) overnight at 4°C. The beads were washed by excess lysis buffer and followed by a wash with TEB buffer (50 mM Tris-HCl, PH 7.5) containing 10% glycerol and 1 mM ATP-MgCl₂. The proteasome holoenzymes were eluted from the beads through cleavage by TEV protease (Invitrogen, CA, USA). The doubly capped proteasome was further purified by gel filtration on a Superose 6 10/300 GL column (GE Healthcare, PA, USA) at a flow rate of 0.15 ml/min in the running buffer (30 mM Hepes pH 7.5, 60 mM NaCl, 1 mM MgCl₂, 10% Glycerol, 0.5 mM DTT, 0.8 mM ATP). The gel-filtration fractions were concentrated to about 2 mg/ml. Measurement of peptidase activity of purified 26S complexes was performed as previously described³.

Cryo-EM Data collection—Immediately before cryo-EM sample preparation, the proteasome sample was mixed with ZFAND5 with a molar ratio about 1:100 and buffer-exchanged into 50 mM Tris-HCl pH 7.5, 1 mM MgCl₂, 1 mM ATP, and 0.005% NP-40 using a 7-kDa Zeba column. Cryo-EM sample grids were prepared using the FEI Vitrobot Mark IV (Thermo Fisher Scientific, MA, USA). C-flat grids (R1.2/1.3; 400 Mesh, Protochips, CA, USA) were glow-discharged before a 2.5- μ l drop of proteasome-ZFAND5 mixed solution was applied to the grids in an environment-controlled chamber with 100% humidity and temperature fixed at 4 °C. After 3 s of blotting, the grid was plunged into liquid ethane and then transferred into liquid nitrogen. The cryo-grids were imaged using a FEI Titan Krios microscope (Thermo Fisher Scientific, MA, USA), equipped with an Autoloader and operating at an acceleration voltage of 300 kV at a nominal magnification of 105,000 times. Cryo-EM movie data were collected using serialEM software on a Gatan K2 Summit direct detector camera in a super-resolution counting mode, with 10 s of total exposure time and 250 ms per frame. Each exposure resulted in a movie of 40 frames with an accumulated dose of 46.6 electrons/Å². The calibrated physical pixel size and the super-resolution pixel size were 1.37 and 0.685 Å per pixel, respectively. The defocus was prescribed in the range from - 0.8 to - 2.5 μ m. A total of 8653 movies in super-resolution mode were collected for data analysis.

Cryo-EM data processing and reconstruction—All frames of the raw movies were first corrected for their gain using a gain reference recorded within 3 days of the acquired movie, after which they were shifted and summed to generate a single micrograph that was corrected for overall drift using the MotionCor2³². Each drift-corrected micrograph was used for the determination of the actual defocus of the micrograph using Gctf program³³. Particle picking was done using DeepEM program³⁹ and 501,131 single particle images were picked for further analysis. The density map of previously published S_A¹⁴ state was low-passed filtered to 60 Å and been used as the initial model.

All the 2D/3D classification and auto-refinement were done in Relion3.0³⁴. The first round 2D/3D classification was done at a pixel size of 2.74 Å and classified the data to two parts, double-capped proteasome with 272,785 particles and single-capped proteasome with 137,130 particles. Then we re-centered particles on RP-CP sub-complexes and converted each double-capped particle to two pseudo single-cap particles by shifting the center to each side^{6,14}. We re-extracted 682,700 pseudo single-cap particles. The second round 2D/3D classification was also done at a pixel size of 2.74 Å and classified the data to CP-gate closed states with 35,4682 pseudo single-cap particles and CP-gate open states with 199,312 pseudo single-cap particles. All the particles in the CP-gate closed states were merged to one class and all the particles in CP-gate open states were merged to another class. Both classes run auto-refinement at the pixel size of 1.37 Å. In the third round, we did focus 3D classification at the pixel size of 1.37 Å with a RP-mask and only did local angular search with angular range of 7.5 degree based on the orientations determined by the auto-refinement in last round. Five different conformational states named state Z_{+A}, Z_{+B}, Z_{+C}, Z_{+D} and Z_{+E} were determined from the CP-gate closed class with particle numbers 80,224, 90,097, 29,419, 46,247 and 28,928 respectively. Three conformations states named Z_{-A}, Z_{-B} and Z_{-C} were determined from CP-gate open class with particle numbers 34,363, 59,461 and 34,075 respectively. After auto-refinement and CTF refinement, the final overall resolutions for Z_{+A}, Z_{+B}, Z_{+C}, Z_{+D}, Z_{+E}, Z_{-A}, Z_{-B} and Z_{-C} are 3.7Å, 3.6Å, 4.3Å, 4.1Å, 4.4Å, 4.7Å, 4.1Å and 4.8Å respectively, measured by gold-standard FSC at 0.143-cutoff on two half maps refined separately. Prior to visualization, all density maps were sharpened by applying a negative B-factor calculated by Relion post-process³⁴. Local resolution variations were estimated using Relion local resolution estimation³⁴.

Atomic model building and refinement—The initial atomic models for 26S proteasome were based on previously published substrate-engaged human 26S structures⁶ and then manually improved the main-chain and sidechain fitting in Coot³⁵ to generate the starting coordinate files. The initial atomic model for ZFAND5 was based on the NMR structure with PDB ID:1WFL and AlphaFold predicted structure¹¹. To fit the model to the reconstructed density map, we first conducted rigid-body fitting of the segments of the model in Chimera³⁸, after which the fit was improved manually in Coot³⁵. Finally, each refinement of the atomic model was carried out in real space with program Phenix.real_space_refine³⁶, with secondary structure and geometry restraints to prevent overfitting.

Structural analysis and visualization—Structural comparison and visualization were conducted in UCSF ChimeraX and Chimera. All figures of the structures were plotted in UCSF ChimeraX³⁷ and Chimera³⁸.

DSSO Cross-linking of Affinity Purified 26S Proteasome-ZFAND5 Complex—The stable 293 cells expressing Rpn1 1-HTBH were grown to ~90% confluence in a DMEM medium containing 10% FBS and 1% Pen/Strep as previously described³⁰. The cells were pelleted and washed with PBS and then lysed in a native lysis buffer [100 mM sodium chloride, 50 mM sodium phosphate, 10% glycerol, 1 mM DTT, 5 mM MgCl₂, 1 mM ATP, 1× protease inhibitor (Roche), 1× phosphatase inhibitor, and 0.5% NP-40 (pH 7.5)].

The lysates were centrifuged at 13,000 rpm for 15 min to remove cell debris, and the supernatant was incubated with streptavidin resin 2 hours at 4 °C. The streptavidin beads were then washed with 50 bed volumes of the lysis buffer, followed by a final wash with 20 bed volumes of crosslinking buffer (150 mM sodium chloride, 25 mM sodium phosphate, 5% glycerol, 5 mM MgCl₂, 1 mM ATP). Bound proteasomes were incubated with equal volume (bed volume) of 70 μM ZFAND5 at 37°C for 30 min, then DSSO was added to the mixture at final concentration of 0.5 mM and incubate for 1 h at 37°C. After quenching the cross-linking reaction, the proteins were reduced/alkylated and digested with LysC/trypsin. Briefly, proteins were digested in 8 M urea buffer using LysC for 4 h at 37 °C, followed by trypsin digestion at 37°C overnight after diluting urea concentration to <1.5 M. The resulting peptide mixtures were extracted and desalted before MS analyses.

Identification of DSSO Cross-Linked Peptides by LC MSⁿ—Peptide digests were analyzed by LC MSⁿ using an UltiMate 3000 RSLC coupled with an Orbitrap Fusion Lumos mass spectrometer similarly as described⁴⁰. Samples were loaded onto a 50 cm x 75 μm Acclaim PepMap C18 column and separated over a 240 min gradient of 4% to 25% acetonitrile at a flow rate of 300 nL/min. The top 4 data-dependent MS³ acquisition method was used for the identification of DSSO cross-linked peptides. Ions with charge of 4+ to 8+ in the MS¹ scan were selected for MS² analysis. The top 4 most abundant fragment ions in MS² scan were further fragmented by CID with a collision energy of 35%. Raw data were extracted by MSConvert and MS³ spectra were subjected to Protein Prospector (v.6.2.13) for database searching using Batch-Tag against SwissProt.2019. 04. 08 random concatenated database. The mass tolerances were set as ±20 ppm for parent ions and 0.6 Da for fragment ions. Trypsin was set as the enzyme with three maximum missed cleavages allowed. Cysteine carbamidomethylation was selected as fix modification. A maximum of three variable modifications were also allowed, including methionine oxidation, N-terminal protein acetylation, and N-terminal conversion of glutamine to pyroglutamic acid. Three defined DSSO cross-linked modification on uncleaved lysines, including alkene (C₃H₂O, +54 Da), thiol (C₃H₂SO, +86 Da) and sulfenic acid (C₃H₄O₂S, +104 Da) were also selected as variable modifications. Search results were integrated via in-house software xl-Tools to identify DSSO cross-linked peptides by the integration of MS¹, MS² and MS³ data.

Purification of recombinant proteins—Recombinant ZFAND5 wild type and mutants containing point mutations in Zn-finger domains (ZFAND5A20mt or ZFAND5AN1mt) were purified as previously described³. Bacterial expression plasmids encoding His₆-ZFAND5 C, His₆-SNAP-ZFAND5wt, His₆-SNAP-ZFAND5 C, His₆-HA-cycB-cpGFP, His₆-HA-cycB-mNeon Green or His₆-HA-cycB-EGFP were generated. All proteins containing hexahistidine-tag (His₆), including E2 UbcH10, ubiquitin and Securin, were purified with Ni-NTA resin (Qiagen).

Recombinant Anaphase Promoting Complex (APC/C) and His₆-Cdh1 were purified from insect cells as previously described⁸.

Labeling proteasomes after purification and in cells with the activity-based probe—26S proteasomes (2nM) were incubated in the reaction buffer (50 mM Tris-HCl

(pH 7.5), 100 mM KCl, 5 mM MgCl₂, 1 mM ATP, 1 mM DTT) and MVB003 (500 nM) (gift from Herman Overkleeft) at 37°C with or without ZFAND5 (500 nM). To label proteasomes in atrophying C2C12 myotubes, cells pretreated with dexamethasone (50µM) for 1d were incubated with MVB003 (500 nM) for 1hr. Samples were resolved in SDS-PAGE and scanned with an AI600 RGB camera with λ_{ex} 520nm and λ_{em} 593nm. Fluorescence of the bands was quantified with the IQTL software package from GE Healthcare Sciences.

Degradation assay with non-ubiquitylated ZFAND5 and 26S proteasome—His₆-ZFAND5 was labeled during expression with ³⁵S- methionine using the kit for coupled transcription/translation system (Promega) and purified with Ni-NTA resin. Purified His-ZFAND5 was incubated with 26S proteasomes up to 60min, and the reactions were stopped by addition of TCA at the indicated time points. Hydrolysis of ³⁵S-His₆-ZFAND5 to TCA-soluble peptides was measured, and the radioactivity in acid soluble and insoluble fractions are presented as the mean ± SD of three replicates.

In vitro ubiquitylation—Ubiquitylation of substrate was performed as described previously^{8,26}. Briefly, polyubiquitylation reactions were performed with 2µM of His₆-HA-cycB-cpGFP, His₆-HA-cycB-mNeonGreen or His₆-HA-cycB-EGFP were by APC/C complex (50nM), 100 nM E1, 2µM UbcH10, 2 mg/ml bovine serum albumin (BSA), 10mM creatine phosphate, 0.1 mg/ml creatine kinase, 10µM ubiquitin in UBAB buffer (25mM Tris-HCl pH 7.5, 50mM NaCl and 10mM MgCl₂) at room temperature for 4h.

Degradation of ubiquitylated substrates—The reaction mixture containing ubiquitylated substrates (120–200nM), 26S proteasomes (2–5nM) and ZFAND5 (0.03–5µM) was incubated in UBAB buffer at 35°C. Degradation of substrate was detected by measurement of fluorescence of cpGFP or EGFP (λ_{ex} , 470 nm; λ_{em} , 510 nm) in 1min interval for 60min. The background level of fluorescent signal from the reaction buffer alone for each time point was subtracted from all the signals with the substrate. The fluorescent signals during degradation reaction were also normalized to small changes in fluorescence from a substrate alone, and then signals relative to that at 0 min were plotted in the figures. Each figure shows the data from at least three independent experiments with 3–5 replicates for each condition. The reactions with ubiquitylated cycB-EGFP were alternatively resolved in SDS-PAGE, and the change in cycB level was probed by the antibody to HA (H9658, Millipore Sigma), ubiquitylation by antibodies to K48-linked chain (#8081, Cell Signaling Technology) or total Ub (#43124, Cell Signaling Technology), and EGFP by GFP antibody (SC-9996, Santa Cruz Biotechnology).

Coimmunoprecipitation assay—Purified 26S proteasomes were immobilized with the antibody to $\alpha 6$ crosslinked on proteinA resin (SC-2001, Santa Cruz Biotechnology). ZFAND5^{wt} or ZFAND5^C was added and incubated for 1h at 4°C. After washing with 300mM NaCl, resin-bound proteins were resolved in SDS-PAGE and probed by Western blot with antibodies to $\alpha 6$ (A303–845A, Bethyl Laboratories), Rpt5 (A303–538A, Bethyl Laboratories) and ZFAND5³.

ZFAND5 was incubated with resin-bound 26S proteasomes for 30min on ice, and resin was washed with the buffer used for degradation assay to remove any free ZFAND5.

CTR peptides were then added to ZFAND5-bound 26S and incubated for 30min on ice. Unbound proteins or peptides were washed off with the reaction buffer, and the levels of proteasome-bound ZFAND5 were determined by Western blot.

Native gel—Purified 26S proteasomes were incubated with or without ZFAND5 for 20min at 37°C and the complexes were resolved in 3–8% gradient native-PAGE. Migration of 26S complexes was detected with the antibody to Rpt5.

Phosphorylation of ubiquitylated substrate—PKA site (RRASV) at the N-terminus of His₆-HA-cycB-cpGFP was radiolabeled with ³²P-ATP, and radiolabeled substrate was then polyubiquitylated by APC/C. Degradation assay was performed as describe above and stopped at the indicated time points in the figure. The levels of ubiquitylated substrates were quantified by a phosphorimager (Typhoon5).

Single-molecule measurement of the kinetics of substrate processing by proteasome in the presence of ZFAND5—Recombinant ubiquitin was labeled with dylight550-maleimide at the N-terminus. The N-terminal His tag was then cleaved off by thrombin and was purified using anion exchange FPLC. Securin labeled with dy550-ubiquitin (Securin-Ub550) was prepared as described previously⁸. Purified 26S proteasome and biotinylated MCP21 antibody were mixed to a final concentration of 20 nM and 12.5 nM respectively. The mixture was incubated at room temperature for 15 min then kept on ice until the experiment. For all imaging experiments, the temperature was set to 29°C ±2°C, unless indicated otherwise. The proteasome-antibody mix was loaded onto passivated slides coated with streptavidin and incubated for 3 min.

For the single-color imaging, unbound proteasome was washed off and replaced with imaging buffer containing diluted 5 nM ubiquitylation product and 500 nM purified ZFAND5 (WT, AN1mt, A20mt, or C). Image acquisition was started immediately with <15 s delay. Time series were acquired at 200 ms per frame for 3 min.

For the dual-color imaging, 2 μM 649-SNAP-ZFAND5 or 2 μM 649-SNAP- ZFAND5 C was prepared by incubating 2 μM of purified SNAP- ZFAND5 with 3 μM SNAP-Surface 649 for 1 hour at room temperature and purified by desalting column. For the experiments, unbound proteasome was washed off and replaced with imaging buffer containing diluted 17 nM ubiquitylation product and 50 nM of either 649-SNAP-ZFAND5 or 649-SNAP-ZFAND5 C. Image acquisition was started immediately with <15 s delay. Time series were acquired at 50 ms per frame for 4000 frames (~3 min). TetraSpeck™ Microspheres, 0.1 μm (T7279) were used to assist color channel registration.

We used a Nikon Ti TIRF microscope equipped with three laser lines of 488 nm (OBIS™ 1277611), 561 nm (Opto Engine MGL-FN-561–100mW, ~1mW at the objective), and 638 nm (Lasever LSR635NL 150 mW, ~0.2mW at the objective), a Nikon Plan Apo λ 100X/ 1.45 Oil objective, and a Pco.edge 4.2 LT HQ camera.

Single-molecule measurement of Ub conjugates binding to ZFAND5—Biotinylated zfan5 was prepared by incubating 2 μM SNAP-ZFAND5 with 1 μM SNAP-

Biotin[®] (S9110S) in UBAB for 1 hour at room temperature. The 2 μ M biotinylated ZFAND5 was loaded onto passivated slides coated with streptavidin and incubated for 5 min. Unbound ZFAND5 was washed off with imaging buffer. Securin-Ub550 diluted in imaging buffer was flowed in at a given concentration and image acquisition was started immediately with <15 s delay. Time series were acquired at 30 ms per frame for 1000 frames (30 seconds).

Analysis of single-molecule data: dwell time, deubiquitylation/translocation kinetics, and dual color processing—Image processing was performed as described previously⁸. In short, image sequences were corrected for stage drift, a custom spot-detection algorithm with <5% false-positive rate identified spots, and the intensity of each spot was obtained by fitting with a two-dimensional Gaussian function. The signal was converted to the copy number of ubiquitin on each substrate molecule by normalizing with the intensity value of a single ubiquitin-550 obtained in the photobleaching calibration step as described previously⁸.

The custom-built algorithm⁸ was used to measure the duration of substrate-binding events. In the dwell time measurement, we did not differentiate whether or not a binding event exhibited processing deubiquitylation.

The measurement of substrate translocation kinetic was performed as previously described⁸. Briefly, a custom-built algorithm was used to align the start of all single-molecule traces showing processive deubiquitylation, i.e. translocation, by the moment of substrate-proteasome interaction. The alignment was manually curated to remove false alignment. The substrate-proteasome interaction was identified by finding the first timepoint where the intensity is at least 80 percent of the maximum intensity within the manually determined start and end times. After alignment, the averaged translocation kinetics was calculated from the intensity average among all the traces at each time point.

For processing dual color imaging, the image sequence was parsed into the two channels. The Securin-Ub550 channel image sequence was processed in the same as described above. The ZFAND5 sequence inherited the corrections for stage drift and the positions of the identified spots from the Ub550 channel image sequence processing. Traces were aligned by the moments of substrate-proteasome interaction, and this alignment was applied to both the ubiquitin and ZFAND5 channel.

Classification of single-molecule binding events—Single-molecule binding events involving both substrate and ZFAND5 were classified manually. Signals lasting only 1 frame (50ms) were not considered as binding events to reduce the influence of background fluctuation.

For the dual color events, the role of ZFAND5 was classified manually:

- The event was determined to have “no ZFAND5” if there was no ZFAND5 signal during or within 10 sec of either side of the Securin-Ub550 binding event.

- If ZFAND5 signal appeared within 10 seconds before the Securin binding event, the event was classified as “ZFAND5 binds before substrate”.
- The event was classified as “simultaneous ZFAND5 & substrate binding” if ZFAND5 signal appeared within one frame of the Securin-Ub550 binding event.
- If ZFAND5 signal appeared after Securin-Ub550 binding to proteasome but before the end of substrate processing or dissociation, this event was classified as “ZFAND5 binding during substrate on proteasome”.
- Finally, a ZFAND5 event was defined as “ZFAND5 binding after substrate dissociation” if the ZFAND5 signal appeared within 10 seconds after the Securin-Ub550 signal disappeared from proteasome.

Live-cell timelapse microscopy—HEK293T cells were transfected with fluorescent reporter constructs, Ub-R-YFP or UbG76V-YFP together with a plasmid expressing wildtype ZFAND5 or mutants from a CMV promoter using TransIT293 following the manufacture’s manual. 36 hours after transfection, cells were replated at about 40% confluency in a 12-well plate. After attachment, 100ug/ml cycloheximide or DMSO was added to the culture and cells were imaged in an Incucyte Zoom imager with 20X objective placed in a conventional tissue culture incubator every 7 minutes.

Calibration of the YFP reporter expression level: HEK293T cells were treated as above. 36 hours post transfection, cells were trypsinized. Cell density and cell volume were immediately measured using a TC20 cell counter. The total fluorescent intensity in the trypsinized culture was determined using a BioTek H1 plate reader and compared with a purified YFP standard. The average cellular YFP concentration was calculated as $[YFP_{\text{culture}}]/(N \cdot V)$, $[YFP_{\text{culture}}]$ is the equivalent YFP concentration in the trypsinized culture; N: cell density; V: cell volume

Data analysis: Processing of timelapse images was performed using P53cinema which is an automatic cell tracking and segmentation software⁴¹. Briefly, each image was preprocessed, background subtracted. Individual cells were identified according to the local fluorescence maxima. The cell boundary was automatically segmented. Cells were automatically tracked along their movement. Tracking and segmentation results were manually verified. The software then calculated the average fluorescent intensity vs. time for each segmented cell. 100~200 cells were analyzed for each condition. To extract the half live, each time trace was fitted with an exponential function to obtain the decay constant using MATLAB, and was registered with the initial reporter concentration calculated based on the calibration.

QUANTIFICATION AND STATISTICAL ANALYSIS

Quantification of western blot and autoradiography results was performed in ImageJ. Quantification of timelapse images was performed using p53Cinema⁴¹. Quantification of single-molecule images was performed using custom software as described in a previous study⁸. All statistical analysis was carried out in standard procedures using MATLAB 2021.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We are grateful for funding from the National Institute of General Medical Sciences (R01 GM134064-01 to YL; R01 GM051923-20 to ALG), the Cure Alzheimer's Fund, the Muscular Dystrophy Association (to ALG), the Edward Mallinckrodt Jr. Foundation Award to YL, NIH R01GM074830 and R35GM145249 to LH, National Natural Science Foundation of China (NNSFC12090054 to QO), and want to thank Ms Amelia Gould for valuable assistance in preparation of this manuscript. We want to thank Jack (Youdong) Mao, Weili Wang and Xuemei Li at Peking University for assistance in cryo-EM technology. The cryo-EM data were collected from the Electron Microscopy Laboratory and Cryo-EM Platform at Peking University. Data processing was supported by High-Performance Computing Platform at Peking University. We would like to acknowledge support of the Nikon Imaging Center at Harvard Medical School for image acquisition and consulting.

References

1. VerPlank JJS, Lokireddy S, Zhao J, and Goldberg AL (2019). 26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. *Proc Natl Acad Sci U S A* 116, 4228–4237. 10.1073/pnas.1809254116. [PubMed: 30782827]
2. Lee D, and Goldberg AL (2022). 26S proteasomes become stably activated upon heat shock when ubiquitination and protein degradation increase. 10.1073/pnas.
3. Lee D, Takayama S, and Goldberg AL (2018). ZFAND5/ZNF216 is an activator of the 26S proteasome that stimulates overall protein degradation. *Proc Natl Acad Sci U S A* 115, E9550–E9559. 10.1073/pnas.1809934115. [PubMed: 30254168]
4. Hishiya A, Iemura S, Natsume T, Takayama S, Ikeda K, and Watanabe K. (2006). A novel ubiquitin-binding protein ZNF216 functioning in muscle atrophy. *EMBO J* 25, 554–564. 10.1038/sj.emboj.7600945. [PubMed: 16424905]
5. de la Pena AH, Goodall EA, Gates SN, Lander GC, and Martin A. (2018). Substrate-engaged 26S proteasome structures reveal mechanisms for ATP-hydrolysis-driven translocation. *Science* (1979) 362. 10.1126/science.aav0725.
6. Dong Y, Zhang S, Wu Z, Li X, Wang WL, Zhu Y, Stoilova-McPhie S, Lu Y, Finley D, and Mao Y. (2019). Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome. *Nature* 565, 49–55. 10.1038/s41586-018-0736-4. [PubMed: 30479383]
7. Collins GA, and Goldberg AL (2017). The Logic of the 26S Proteasome. *Cell* 169, 792–806. 10.1016/j.cell.2017.04.023.
8. Lu Y, Lee BH, King RW, Finley D, and Kirschner MW (2015). Substrate degradation by the proteasome: a single-molecule kinetic analysis. *Science* (1979) 348, 1250834. 10.1126/science.1250834.
9. Yu H, and Matouschek A. (2017). Recognition of Client Proteins by the Proteasome. *Annu Rev Biophys* 46, 149–173. 10.1146/annurev-biophys-070816-033719. [PubMed: 28301771]
10. Cohen S, Nathan JA, and Goldberg AL (2015). Muscle wasting in disease: molecular mechanisms and promising therapies. *Nat Rev Drug Discov* 14, 58–74. 10.1038/nrd4467. [PubMed: 25549588]
11. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A, et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature* 596, 583–589. 10.1038/s41586-021-03819-2. [PubMed: 34265844]
12. Wang X, Cimermancic P, Yu C, Schweitzer A, Chopra N, Engel JL, Greenberg C, Huszagh AS, Beck F, Sakata E, et al. (2017). Molecular Details Underlying Dynamic Structures and Regulation of the Human 26S Proteasome. *Mol Cell Proteomics* 16, 840–854. 10.1074/mcp.M116.065326. [PubMed: 28292943]
13. Chen S, Wu J, Lu Y, Ma YB, Lee BH, Yu Z, Ouyang Q, Finley DJ, Kirschner MW, and Mao Y. (2016). Structural basis for dynamic regulation of the human 26S proteasome. *Proc Natl Acad Sci U S A* 113, 12991–12996. 10.1073/pnas.1614614113. [PubMed: 27791164]

14. Zhu Y, Wang WL, Yu D, Ouyang Q, Lu Y, and Mao Y. (2018). Structural mechanism for nucleotide-driven remodeling of the AAA-ATPase unfoldase in the activated human 26S proteasome. *Nat Commun* 9, 1360. 10.1038/s41467-018-03785-w. [PubMed: 29636472]
15. Unverdorben P, Beck F, Sledz P, Schweitzer A, Pfeifer G, Plitzko JM, Baumeister W, and Forster F. (2014). Deep classification of a large cryo-EM dataset defines the conformational landscape of the 26S proteasome. *Proc Natl Acad Sci U S A* 111, 5544–5549. 10.1073/pnas.1403409111. [PubMed: 24706844]
16. Shi Y, Chen X, Elsasser S, Stocks BB, Tian G, Lee BH, Shi Y, Zhang N, de Poot SA, Tuebing F, et al. (2016). Rpn1 provides adjacent receptor sites for substrate binding and deubiquitination by the proteasome. *Science* (1979) 351. 10.1126/science.aad9421.
17. Rabi J, Smith DM, Yu Y, Chang SC, Goldberg AL, and Cheng Y. (2008). Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. *Mol Cell* 30, 360–368. 10.1016/j.molcel.2008.03.004. [PubMed: 18471981]
18. Choi WH, de Poot SA, Lee JH, Kim JH, Han DH, Kim YK, Finley D, and Lee MJ (2016). Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. *Nat Commun* 7, 10963. 10.1038/ncomms10963. [PubMed: 26957043]
19. Li N, Kuo CL, Paniagua G, van den Elst H, Verdoes M, Willems LI, van der Linden WA, Ruben M, van Genderen E, Gubbens J, et al. (2013). Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. *Nat Protoc* 8, 1155–1168. 10.1038/nprot.2013.065. [PubMed: 23702832]
20. Pédelacq JD, Cabantous S, Tran T, Terwilliger TC, and Waldo GS (2006). Engineering and characterization of a superfolder green fluorescent protein. *Nat Biotechnol* 24, 79–88. 10.1038/nbt1172. [PubMed: 16369541]
21. Khmelinskii A, Meurer M, Ho CT, Besenbeck B, Fuller J, Lemberg MK, Bukau B, Mogk A, and Knop M. (2016). Incomplete proteasomal degradation of green fluorescent proteins in the context of tandem fluorescent protein timers. *Mol Biol Cell* 27, 360–370. 10.1091/mbc.E15-07-0525. [PubMed: 26609072]
22. Kirkpatrick DS, Hathaway NA, Hanna J, Elsasser S, Rush J, Finley D, King RW, and Gygi SP (2006). Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. *Nat Cell Biol* 8, 700–710. 10.1038/ncb1436. [PubMed: 16799550]
23. Nassif ND, Cambray SE, and Kraut DA (2014). Slipping up: partial substrate degradation by ATP-dependent proteases. *IUBMB Life* 66, 309–317. 10.1002/iub.1271. [PubMed: 24823973]
24. Matyskiela ME, Lander GC, and Martin A. (2013). Conformational switching of the 26S proteasome enables substrate degradation. *Nat Struct Mol Biol* 20, 781–788. 10.1038/nsmb.2616. [PubMed: 23770819]
25. Verma R, Aravind L, Oania R, McDonald WH, Yates JR, Koonin E. v., and Deshaies RJ (2002). Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. *Science* (1979) 298, 611–615. 10.1126/science.1075898.
26. Fang R, Hon J, Zhou M, and Lu Y. (2022). An empirical energy landscape reveals mechanism of proteasome in polypeptide translocation. *Elife* 11. 10.7554/eLife.71911.
27. Strachan J., Roach L., Sokratous K., Tooth D., Long J., Garner TP., Searle MS., Oldham NJ., and Layfield R. (2012). Insights into the molecular composition of endogenous unanchored polyubiquitin chains. In *Journal of Proteome Research*, pp. 1969–1980. 10.1021/pr201167n.
28. Lokireddy S, Kukushkin N. v, and Goldberg, A.L. (2015). cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. *Proc Natl Acad Sci U S A* 112, E7176–85. 10.1073/pnas.1522332112. [PubMed: 26669444]
29. Medina R, Wing SS, and Goldberg AL (1995). Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy.
30. Wang X, Chen CF, Baker PR, Chen PL, Kaiser P, and Huang L. (2007). Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. *Biochemistry* 46, 3553–3565. 10.1021/bi061994u. [PubMed: 17323924]
31. Mastronarde DN (2005). Automated electron microscope tomography using robust prediction of specimen movements. *J Struct Biol* 152, 36–51. 10.1016/j.jsb.2005.07.007. [PubMed: 16182563]

32. Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, and Agard DA (2017). MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 14, 331–332. 10.1038/nmeth.4193. [PubMed: 28250466]
33. Zhang K. (2016). Gctf: Real-time CTF determination and correction. *J Struct Biol* 193, 1–12. 10.1016/j.jsb.2015.11.003. [PubMed: 26592709]
34. Egelman EH, Zivanov J, Nakane T, rn Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, and Scheres SH (2018). New tools for automated high-resolution cryo-EM structure determination in RELION-3. 10.7554/eLife.42166.001.
35. Emsley P, and Cowtan K. (2004). Coot: Model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60, 2126–2132. 10.1107/S0907444904019158. [PubMed: 15572765]
36. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. (2010). PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66, 213–221. 10.1107/S0907444909052925. [PubMed: 20124702]
37. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, and Ferrin TE (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci* 30, 70–82. 10.1002/pro.3943. [PubMed: 32881101]
38. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera - A visualization system for exploratory research and analysis. *J Comput Chem* 25, 1605–1612. 10.1002/jcc.20084. [PubMed: 15264254]
39. Zhu Y, Ouyang Q, and Mao Y. (2017). A deep convolutional neural network approach to single-particle recognition in cryo-electron microscopy. *BMC Bioinformatics* 18. 10.1186/s12859-017-1757-y.
40. Yu C, Wang X, Huszagh AS, Viner R, Novitsky E, Rychnovsky SD, and Huang L. (2019). Probing H2O2-mediated structural dynamics of the human 26s proteasome using quantitative cross-linking mass spectrometry (QXL-MS). *Molecular and Cellular Proteomics* 18, 954–967. 10.1074/mcp.TIR119.001323. [PubMed: 30723094]
41. Reyes J., Chen JY., Stewart-Ornstein J., Karhohs KW., Moc CS., and Lahav G. (2018). Fluctuations in p53 Signaling Allow Escape from Cell-Cycle Arrest. *Mol Cell* 71, 581–591.e5. 10.1016/j.molcel.2018.06.031. [PubMed: 30057196]

Highlights

- ZFAND5's C-terminal domain is necessary and sufficient for 26S proteasome activation
- ZFAND5 ferries substrate to the proteasome and dissociates upon translocation
- ZFAND5 interacts with the 19S proteasome and induces a distinct 19S conformation
- ZFAND5 binding broadens the ATPase channel entrance, enhancing substrate commitment




Figure 1. Cryo-EM structures of the human 26S proteasome complexed with ZFAND5/ZNF216. (A) Selected cryo-EM density maps of human 26S proteasomes in the presence of ZFAND5 (red). The relative abundances of each 3D class (% total). Z^+ refers to each class containing a ZFAND5 density and Z^- to classes lacking ZFAND5. As shown below, the domain architecture of ZFAND5 is shown on the right. (B) A local view of ZFAND5 in the cryo-EM density map of the Z^+D state. Close-up views of ZFAND5's interfaces with various proteasome subunits are shown in D, with regions of same color indicated in the top panel. (C) A local view of the Z^+D model highlighting the molecular path that ZFAND5

follows on by Rpt5, Rpt1 and Rpn1 and the positions of its C-terminal residues in **Z+D**. (D) Close-up views of ZFAND5's interfaces with various proteasome subunits are shown in the lower panels with the same colors as in B. (E) Chemically-crosslinked residue pairs in a proteasome-ZFAND5 sample were identified by mass spectrometry and are represented as dotted lines. See also Figures S1–S4 and Tables S1 and S2.




Figure 2. ZFAND5 induces a 19S conformation with an open entry to the substrate translocation channel in the $Z+D$ state.

(A) Comparison of the structures of the ATPase and the non-ATPase parts in $Z+D$ (left panel) and $Z+A$ states. Superimposed on $Z+D$ conformation (right panel) are shown in gray the locations of the corresponding subunits in $Z+A$, which are very similar in $Z+B$ and $Z+C$. (B) Comparison of the entrance to the substrate translocation channel in three different 19S states. The diameter of the unobstructed part of the entrance is indicated by an arrow. Lower: vertical cross sections of cryo-EM maps. Substrate translocation channel's interior residues

are colored red, surface delineated by dashed lines. (C) Close-up views showing relocation of Rpn3's C-terminal domain leading to unimpeded entry to the ATPase channel in **Z+D** states. (D) ZFAND5 increases access to active sites in the CP. An activity-based probe MVB003 for the active sites in the CP was incubated with 26S proteasome in the presence or absence of ZFAND5. Samples were analyzed by SDS electrophoresis and fluorescence imaging. (E) ZFAND5 C mutant lacking its 19 C-terminal residues binds to the 26S proteasome. Co-immunoprecipitation with immobilized anti- α 1 antibody or control IgG. The bound samples were analyzed by Western blotting (WB). (F) The peptidase activity of 26S proteasome in the presence of ZFAND5 or its C mutant. Right: Coomassie staining of purified ZFAND5. Error bars represent SD of three replicates. (G) Change in migration of proteasomes by ZFAND5 requires its C-terminus. 26S proteasomes were incubated with ZFAND5 or its C mutant and were analyzed by native electrophoresis and by WB. (H) Induction of ZFAND5 by dexamethasone leads to proteasome gate opening shown by reactivity with MVB003. C2C12 myotubes were treated with dexamethasone (50mM) for 1 day and with MVB003 for 1h before harvesting. The labeled 20S subunits were resolved in SDS-PAGE, and proteasome contents were compared by WB. See also Figures S5–S9 and Tables S1 and S2.




Figure 3. ZFAND5 stimulates the degradation of Ub conjugates by the 26S proteasome. (A) Intensities of a fluorescent substrate, ubiquitylated cycB-cpGFP, upon degradation reactions with purified 26S proteasomes and ZFAND5 at various concentrations. CycB-cpGFP's degradation rates calculated from the slopes at the initial ("I") or late ("II") stage of the reaction are listed in the table. Shown are the mean rates ± the standard deviations (SD) of five replicates. The degradation rates for the indicated time frames (I and II) are shown ± SD from three independent experiments. (B) Effect of ZFAND5 on the degradation of substrates containing increasing numbers of Ub molecules. ³²P-labeled ubiquitylated

cycB-cpGFP was incubated with 26S proteasomes and ZFAND5. Samples were analyzed by autoradiography and the degradation rate of each ubiquitylated species was plotted on the right. Error bars represent uncertainty in quantification. (C) ZFAND5's C-terminal 19 residues, A20 domain and AN1 domain are essential for the stimulation of degradation. Reactions were performed as in A but with ZFAND5 mutants. Error bars represent the SD of five replicates. (D) Effects of ZFAND5 and its mutants on the mean half-lives of, Ub-R-YFP, a substrate of the N-end rule pathway, and Ub-(G76V)-YFP, a substrate of the UFD pathway in cells. Degradation of these substrates was monitored using time-lapse microscopy in a cycloheximide chase experiment in HEK293 cells cotransfected with ZFAND5 WT or mutants. Cells expressing 5~15uM reporters were selected. 15~50 cells were analyzed in each category. Error bars represent the standard errors and the statistical significance is marked by “*”. The expression levels of FLAG-ZFAND5WT and mutants were examined by WB. (E) ZFAND5 stimulates the degradation of naturally ubiquitylated proteins, which were isolated from HEK293 cells expressing polyHis-HA-tagged Ub, followed by incubation with purified 26S proteasome with or without ZFAND5. The samples were analyzed for K48 Ub linkage and HA epitope by WB. Error bars represent the SD of three replicates. See also Figure S10.




Figure 4. ZFAND5 stimulates deubiquitylation and degradation of unfolding-resistant substrate by the 26S proteasome.

(A) Ubiquitylated cycB-EGFP was incubated with 26S proteasome in the presence of WT and mutant ZFAND5 in (B). Levels of cycB, EGFP and ubiquitylation were determined by WB. Error bars represent the SD of three replicates. (C) Stimulation of degradation and deubiquitylation requires Rpn11. Degradation assays were performed as in (A), but in the presence of the cysteine DUB inhibitor Ub-VS or the Rpn11 inhibitor 8MQ. Error bars represent uncertainty in quantification. See also Figure S11.




Figure 5. A 19-residue peptide from ZFAND5's C-terminus by itself activates proteasomal degradation of short peptides and Ub conjugates.

(A) The chymotryptic peptidase activity of purified 26S proteasome was determined in the presence of indicated peptides. Error bars represent the SD of three replicates. (B) The CTR peptide stimulates degradation of ubiquitylated substrates. Increasing concentrations of the CTR peptide were incubated with ubiquitylated cycB-cpGFP and 26S, and degradation was measured by fluorescence intensity. The degradation rates during the indicated time frame are presented \pm SD from three replicates. (C) Mutagenesis of the proteasome-interacting residues of ZFAND5 and the effects on proteasome activation. The peptidase activity was determined as in A, but with indicated ZFAND5 variants. (D) As in B, but in the presence of indicated ZFAND5 variants. Results are presented as the mean \pm SD of three replicates. See also Figure S12.




Figure 6. ZFAND5 exhibits two binding modes on the 26S proteasome and enhances substrate-proteasome interaction.

(A) ZFAND5's C-terminal region is essential for the stimulation of substrate association with the proteasome. Schematic and typical images of the single-molecule assay testing the interaction of fluorescent ZFAND5 with surface-immobilized 26S particles. Scale bars = 5 μ m (B) Distribution of ZFAND5's dwell times on the proteasome. The measurements were fitted with a double exponential function and the two exponents are plotted as straight lines on a semi-log scale. (C) Amplitude of the second (i.e. long-binding mode) exponential component of ZFAND5's dwell time distribution. Measurement and data

processing were performed as in B in the presence of ZFAND5, or ZFAND5 C, or upon addition of ATP- γ S. Error bars represent fitting uncertainty. (D) Schematic and sample images of the single-molecule assay to study the interactions of securin conjugated with Dy550-Ub and immobilized ZFAND5 WT or C. The average dwell-time of a securin molecule on ZFAND5 is shown in (E). (F) Schematic and sample images of the single-molecule fluorescence analysis of the kinetics of substrate processing by immobilized 26S proteasomes. (G) The average dwell-time of a securin molecule conjugated with Dy550-Ub on the 26S proteasome in the presence of 500 μ M ZFAND5 or its mutants was plotted vs. the number of Ub molecules per substrate molecule. Inset: the ratio of the dwell-time values in the presence and absence of ZFAND5. See also Figure S13.




Figure 7. ZFAND5 ferries Ub conjugates to the proteasome and promotes their deubiquitylation and proteolysis.

(A) Examples of single-molecule traces exhibiting processive deubiquitylation. Shown are the number of Ub molecules lost with each deubiquitylation step. (B) Effects of ZFAND5 and its mutants on the fraction of all substrate-proteasome encounters leading to processive deubiquitylation. Substrates containing at least four Ubs were analyzed. Error bars represent the SD of three replicates. (C) An example montage and the time trajectory from a single-molecule measurement of ZFAND5 and ubiquitylated securin interacting with immobilized 26S proteasomes and undergoing dissociation or deubiquitylation. ZFAND5 was labeled

with a JF646 dye via a SNAP tag; Ub was labeled with Dy550. (D) Comparison of ZFAND5 dwell times on proteasomes when leading to processive deubiquitylation or not. “*” indicates the statistical significance. (E) The fraction of substrate binding events leading to processive deubiquitylation when ZFAND5 binds with, before or after the substrate. See methods for the definition of each category. Error bars represent the SD of three replicates. (F) ZFAND5, but not its A20 mutant or C-terminal deletion, increases the frequency of simultaneous binding with substrate to the proteasome. The fraction of times that the substrate binds together with, before, or after ZFAND5 or its mutants. (G) The averaged single-molecule kinetics of ZFAND5 and ubiquitylated securin on proteasome, suggesting that ZFAND5 dissociates from proteasomes before securin undergoes deubiquitylation. Single-molecule events recorded in the presence of ZFAND5 (N=440) or ZFAND5 C (N=97) were aligned by the moment of securin binding to proteasome, and the average fluorescence intensities among these events were plotted for the Ub and ZFAND5 channels. (H) ZFAND5 stimulates Ub conjugate degradation through a multistep reaction cycle 1) Formation of ZFAND5-substrate complex. 2) Its association with the proteasome RP. 3) RP assumes an open-channel conformation (Z+D) that favors deubiquitylation and degradation. 4) ZFAND5 dissociation leads to CP-gate opening, alignment with ATPase channel and substrate translocation into CP. See also Figure S14.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Ubiquitin (E4I2J) Rabbit mAb	Cell Signaling Technology	Cat# 43124S
K48-linkage Specific Polyubiquitin (D9D5) Rabbit mAb	Cell Signaling Technology	Cat# 8081S
Monoclonal Anti-HA antibody	Millipore Sigma	Cat# H9658
GFP Antibody (B-2)	Santa Cruz Biotechnology	Cat# sc-9996
ZFAND5 antibody	Lee et al. 2018 ³	N/A
Rpt5 antibody	Bethyl Laboratories	A303–538A
PSMB5 antibody	Bethyl Laboratories	A303–847A
PSMA6 antibody	Gift Kisselev Lab, Auburn Univ.	N/A
Bacterial and virus strains		
NiCo21 (DE3)	NEB	C2529H
Turbo	NEB	C2984H
Chemicals, peptides, and recombinant proteins		
8-Mercaptoquinoline Hydrochloride	Fisher Scientific	A50041G
Protein A resin	Santa Cruz Biotechnology	SC-2001
Peptide corresponding to ZFAND5 amino acids 195–213	Tufts Analytical Core	N/A
His ₆ -ZFAND5	This study	N/A
His ₆ -ZFAND5 C	This study	N/A
ZFAND5 from GST-ZFAND5	Hishiya et al. 2006 ⁴	N/A
ZFAND5 A20mt (M1) from GST-ZFAND5A20mt	Hishiya et al. 2006 ⁴	N/A
ZFAND5 AN1mt (M2) from GST-ZFAND5AN1mt	Hishiya et al. 2006 ⁴	N/A
A20mt/AN1 (M3) from GST-ZFAND5 A20mt/AN1	Hishiya et al. 2006 ⁴	N/A
His ₆ -ZFAND5N202A	This study	N/A
His ₆ -ZFAND5P203A	This study	N/A
His ₆ -ZFAND5K209A	This study	N/A
His ₆ -ZFAND5I213A	This study	N/A
His ₆ -ZFAND5N202A+P203A	This study	N/A
His ₆ -ZFAND5K209A+I213A	This study	N/A
His ₆ -ZFAND54mt (N202A+P203A+K209A+I213A)	This study	N/A
Critical commercial assays		
TnT [®] T7 Quick for PCR DNA	Promega	L5540
Deposited data		
26S proteasome Zfand5 complex Z _A state	This study	EMD-14201, PDB: 7QXN
26S proteasome Zfand5 complex Z _B state	This study	EMD-14202, PDB: 7QXP
26S proteasome Zfand5 complex Z _C state	This study	EMD-14203, PDB: 7QXU
26S proteasome Zfand5 complex Z _D state	This study	EMD-14204, PDB: 7QXW

REAGENT or RESOURCE	SOURCE	IDENTIFIER
26S proteasome Zfand5 complex Z ₊ E state	This study	EMD-14205, PDB: 7QXX
26S proteasome Zfand5 complex Z ₋ A state	This study	EMD-14209, PDB: 7QY7
26S proteasome Zfand5 complex Z ₋ B state	This study	EMD-14210, PDB: 7QYA
26S proteasome Zfand5 complex Z ₋ C state	This study	EMD-14211, PDB: 7QYB
Raw data for main figures(1~7), Supp. Figures and Table S1 are deposited on Mendeley Data	This study	DOI: 10.17632/wkw5y7xzb3.1
Experimental models: Cell lines		
HEK293 expressing hRpn11-HTBH	Wang et al. 2007 ³⁰	N/A
HEK293 expressing His ₆ -HA-Ub	This study	N/A
Recombinant DNA		
pCMV4-ZFAND5	This study	N/A
pF-ZFAND5 A20mt (M1)	Hishiya et al. 2006 ⁴	N/A
pF-ZFAND5 AN1mt (M2)	Hishiya et al. 2006 ⁴	N/A
pF-ZFAND5 A20mt/AN1 (M3)	Hishiya et al. 2006 ⁴	N/A
pCMV4-ZFAND5 C	This study	N/A
Ub-R-YFP	Addgene	11948
Ub-G76V-YFP	Addgene	11949
Software and algorithms		
Serial EM	Mastrorarde, et al., 2005 ³¹	https://bio3d.colorado.edu/SerialEM/
MotionCor2	Zheng et al., 2017 ³²	https://emcore.ucsf.edu/ucsf-software
Gctf	Zhang, et al., 2016 ³³	https://sbgrid.org/software/titles/gctf
Relion3.0	Egelman et al., 2018 ³⁴	https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Main_Page
Coot	Emsley and Cowtan, 2004 ³⁵	https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/
Phenix	Adams et al., 2010 ³⁶	https://phenix-online.org/
UCSF ChimeraX	Pettersen et al., 2021 ³⁷	https://www.rbvi.ucsf.edu/chimerax/
UCSF Chimera	Pettersen et al., 2004 ³⁸	https://www.cgl.ucsf.edu/chimera/
AlphaFold	Jumper et al., 2021 ¹¹	https://alphafold.ebi.ac.uk/